Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-OncoCAIX
- Development stage
- Phase 1
- Lead developer
- Philogen
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-OncoCAIX is a small molecule radiopharmaceutical designed as a PET imaging agent. It consists of a high-affinity organic ligand targeting Carbonic Anhydrase IX (CAIX), an innovative spacer, and a DOTAGA chelator for the incorporation of the radioisotope Gallium-68. CAIX is highly expressed in most renal cell carcinomas and other hypoxic tumors, such as some colorectal carcinomas and high-grade gliomas. The compound demonstrates rapid, selective tumor accumulation with low kidney uptake in preclinical models. Its primary use is for non-invasive imaging of CAIX-positive cancers, particularly clear cell renal cell carcinoma. A first-in-human Phase I clinical trial has been approved to evaluate its safety and dosimetry[1][2][4].
- Other names
- Gallium-68-OncoCAIXGallium68-OncoCAIXGallium 68-OncoCAIX
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on 68Ga-OncoCAIX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-OncoCAIX.